Capital Investment Advisors LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 2.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 242,378 shares of the biopharmaceutical company’s stock after selling 6,285 shares during the quarter. Capital Investment Advisors LLC’s holdings in Gilead Sciences were worth $14,409,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wolf Group Capital Advisors grew its holdings in Gilead Sciences by 200.0% in the fourth quarter. Wolf Group Capital Advisors now owns 128,271 shares of the biopharmaceutical company’s stock worth $9,314,000 after purchasing an additional 85,514 shares during the last quarter. Congress Wealth Management LLC DE purchased a new position in Gilead Sciences in the fourth quarter worth $419,000. WBI Investments Inc. grew its holdings in Gilead Sciences by 10.4% in the fourth quarter. WBI Investments Inc. now owns 46,422 shares of the biopharmaceutical company’s stock worth $3,249,000 after purchasing an additional 4,371 shares during the last quarter. Mystic Asset Management Inc. purchased a new position in Gilead Sciences in the fourth quarter worth $33,000. Finally, TCW Group Inc. grew its holdings in Gilead Sciences by 3.8% in the fourth quarter. TCW Group Inc. now owns 699,145 shares of the biopharmaceutical company’s stock worth $50,765,000 after purchasing an additional 25,768 shares during the last quarter. 80.16% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have recently weighed in on GILD shares. StockNews.com started coverage on shares of Gilead Sciences in a report on Thursday, March 31st. They set a “buy” rating on the stock. SVB Leerink started coverage on shares of Gilead Sciences in a report on Monday, May 23rd. They set a “market perform” rating and a $68.00 price objective on the stock. Barclays dropped their price objective on shares of Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating on the stock in a report on Thursday, March 10th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. Finally, BMO Capital Markets initiated coverage on shares of Gilead Sciences in a report on Tuesday, June 7th. They set a “hold” rating and a $63.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and an average target price of $72.07.
Gilead Sciences (NASDAQ:GILD – Get Rating) last released its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.77 by $0.35. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.28 billion. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the business posted $2.08 earnings per share. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 6.59 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Investors of record on Wednesday, June 15th will be paid a dividend of $0.73 per share. The ex-dividend date of this dividend is Tuesday, June 14th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.75%. Gilead Sciences’s payout ratio is 81.56%.
Gilead Sciences Profile (Get Rating)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.